Chromosomally integrated human herpesvirus 6: questions and answers

Philip E. Pellett1*, Dharam V. Ablashi2, Peter F. Ambros3, Henri Agut4, Mary T. Caserta5, Vincent Descamps6, Louis Flamand7, Agnès Gautheret-Dejean4, Caroline B. Hall8, Rammurti T. Kamble9, Uwe Kuehl10, Dirk Lassner11, Irmeli Lautenschlager12, Kristin S. Loomis2, Mario Luppi13, Paolo Lusso14, Peter G. Medveczky15, Jose G. Montoya16, Yasuko Mori17, Masao Ogata18, Joshua C. Pritchett2, Sylvie Rogez19, Edward Seto20, Katherine N. Ward21, Tetsushi Yoshikawa22 and Raymund R. Razonable23**

1Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI, USA
2HHV-6 Foundation, Santa Barbara, CA, USA
3Children’s Cancer Research Institute, Vienna, Austria
4Service of Virology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
5Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY, USA
6Department of Dermatology, Bichat Claude Bernard Hospital, Paris, France
7Rheumatology and Immunology Research Center, Université Laval, Quebec, Canada
8Departments of Pediatrics and Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
9Hematology & Oncology, Baylor College of Medicine, Houston, TX, USA
10Cardiology and Pneumonology, Charité University Berlin, Berlin, Germany
11Institute for Cardiac Diagnosis & Treatment, Berlin, Germany
12Department of Virology, HLSLAB & University of Helsinki, Helsinki, Finland
13University of Modena and Reggio Emilia, Emilia–Romagna, Italy
14National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA
15Department of Molecular Medicine, University of South Florida, Tampa, FL, USA
16Department of Infectious Disease, Stanford University, Stanford, CA, USA
17Division of Clinical Virology, Kobe University, Kobe, Hyōgo, Japan
18Hematology, Blood Transfusion Center, Oita University, Oita, Japan
19Department of Virology, CHRU Dupuytren, Limoges, France
20Department of Molecular Oncology, Moffitt Cancer Center & Research Institute, USA
21Department of Infection, University College London, London, UK
22Department of Pediatrics, Fujita Health University, Toyoake, Aichi, Japan
23Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA

SUMMARY

Chromosomally integrated human herpesvirus 6 (ciHHV-6) is a condition in which the complete HHV-6 genome is integrated into the host germ line genome and is vertically transmitted in a Mendelian manner. The condition

*Correspondence to: P. E. Pellett, PhD, Professor, Department of Immunology, and Microbiology, Wayne State University, 6225 Scott Hall, 540 East Canfield Avenue, Detroit, MI 48201.
E-mail: ppellett@med.wayne.edu

**Correspondence to: R. Razonable, MD, Associate Professor, Division of Infectious Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
E-mail: razonable.raymund@mayo.edu

Abbreviations used:
AHS, anticonvulsant-induced hypersensitivity syndrome; ALL, acute lymphocytic leukemia; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug rash with eosinophilia and systemic symptoms; FDA, United States’ Food and Drug Administration; FISH, fluorescence in situ hybridization; GVHD, graft-versus-host disease; HDAC, histone deacetylase; HSCT, hematopoietic stem cell transplantation; SJS, Stevens–Johnson syndrome; SOT, solid organ transplantation; TEN, toxic epidermal necrolysis.

Copyright © 2011 John Wiley & Sons, Ltd.
is found in less than 1% of controls in the USA and UK, but has been found at a somewhat higher prevalence in transplant recipients and other patient populations in several small studies. HHV-6 levels in whole blood that exceed 5.5 log10 copies/ml are strongly suggestive of ciHHV-6. Monitoring DNA load in plasma and serum is unreliable, both for identifying and for monitoring subjects with ciHHV-6 due to cell lysis and release of cellular DNA. High HHV-6 DNA loads associated with ciHHV-6 can lead to erroneous diagnosis of active infection. Transplant recipients with ciHHV-6 may be at increased risk for bacterial infection and graft rejection. ciHHV-6 can be induced to a state of active viral replication \textit{in vitro}. It is not known whether ciHHV-6 individuals are put at clinical risk by the use of drugs that have been associated with HHV-6 reactivation \textit{in vivo} or \textit{in vitro}. Nonetheless, we urge careful observation when use of such drugs is indicated in individuals known to have ciHHV-6. Little is known about whether individuals with ciHHV-6 develop immune tolerance for viral proteins. Further research is needed to determine the role of ciHHV-6 in disease. Copyright © 2011 John Wiley & Sons, Ltd.

Supporting information can be found in the online version of this article.

Received: 9 August 2011; Revised: 2 September 2011; Accepted: 15 September 2011

INTRODUCTION

This is a review of chromosomally integrated human herpesvirus 6 (ciHHV-6) and its potential clinical implications (Table 1), in the form of a series of questions and answers. The major points are summarized in Table 2. In many areas, available data are insufficient to support evidence-based guidance, leaving us with our opinions. We provide a list of research questions (Table 3) to motivate studies that will allow more extensive evidence-based guidance to be offered in several years. Table 4 lists drugs associated with HHV-6 reactivation; an expanded version is provided in Supplemental Table 1. Background information about human herpesvirus 6 (HHV-6) and ciHHV-6 is available elsewhere [1–6].

What is human herpesvirus 6?

Human herpesvirus 6 is the collective name for HHV-6A and HHV-6B, which are two closely related herpesviruses that have a combined seroprevalence of >90% in adults. HHV-6B is typically transmitted via saliva and primary infection usually occurs between 6 months and 2–3 years of age. Many primary HHV-6B infections are not associated with any specific clinical features, although the virus causes roseola infantum (exanthema subitum or sixth disease) in ~30% of children, presenting with high-grade fever followed by a characteristic rash that is sometimes accompanied by benign febrile convulsions, and rarely by status epilepticus. Little is known about primary HHV-6A infection and its disease associations. For the 99% of the

Table 1. Clinical scenarios that may be associated with ciHHV-6

Misdiagnosis of active HHV-6 infection in ciHHV-6 individuals presenting with unconnected illnesses.
Incidental positivity of CSF PCR for HHV-6 in ciHHV-6 patients with CSF pleocytosis resulting in erroneous diagnosis and unnecessary treatment.
Persistence of high levels of HHV-6 genomes (high HHV-6 DNA copy numbers).
Transmission of ciHHV-6 hematopoietic cells from donor to recipient following allogeneic HSCT.
Presence of high levels of HHV-6 DNA in the non-hematopoietic tissues but not in the hematopoietic tissues of a ciHHV-6 individual who received a non-ciHHV-6 HCST.
Transplantation of a solid organ from an individual with ciHHV-6 to a recipient without ciHHV-6.
Potential for ciHHV-6 reactivation in immunocompromised hosts.
Potential for ciHHV-6 reactivation in individuals treated with certain drugs.
Increased risk of bacterial infection in SOT recipients with ciHHV-6.
Uncertainty as to whether to treat ciHHV-6 patients who have symptoms associated with HHV-6 activity, such as CNS dysfunction.

ciHHV-6, chromosomally integrated human herpesvirus 6; HHV-6, human herpesvirus 6; HSCT, hematopoietic stem cell transplantation; SOT, solid organ transplantation.
population without ciHHV-6, most become infected with the virus in the first 2 years of life, with the virus establishing latency in a small fraction of mononuclear cells.

Disease associated with HHV-6A and HHV-6B reactivations can occur in immunocompromised hosts, and rarely in immunocompetent individuals. HHV-6B reactivation often occurs in immunocompetent individuals during drug induced hypersensitivity syndrome (DIHS) and the related drug rash with eosinophilia and systemic symptoms (DRESS). Symptoms and conditions that have been firmly associated with HHV-6B in immunocompromised patients include exanthematous rash, fever, seizures [7], encephalopathy [8], limbic encephalitis [9] and amnesia [10,11], cognitive dysfunction [12], lymphadenopathy [13], colitis [14–16], and hepatitis [17,18].

Table 2. ciHHV-6: Key points

| What is ciHHV-6? | ciHHV-6 is a condition in which the complete HHV-6 genome is integrated into the host germline genome and is transmitted in a Mendelian manner. |
| Why does it matter? | The high HHV-6 DNA load in patients with ciHHV-6 can lead to misdiagnosis due to the incorrect assumption that the patient is experiencing active HHV-6 infection for which antiviral treatment might be warranted. A hypothetical risk is that clinical or environmental exposure to certain drugs and chemicals may inadvertently activate the virus in patients with ciHHV-6. |
| How can ciHHV-6 be diagnosed? | HHV-6 levels in whole blood that exceed 5.5 log_{10} copies/ml are strongly suggestive of ciHHV-6. This can be confirmed if the ratio of viral to human genomes is about 1:1. |
| Should ciHHV6 individuals be treated for HHV-6? | It is unknown if individuals with ciHHV-6 have viral activity that would benefit from intervention. Antiviral therapy might be warranted in individuals with ciHHV-6 if they have clinical manifestations compatible with those typically associated with HHV-6 disease in the immunocompromised, and alternative concurrent etiologies have been excluded. |

Table 3. Important areas for further research related to ciHHV-6

| What is the prevalence of ciHHV-6 in populations of various geographic, cultural, and socioeconomic origins? |
| What are the consequences of ciHHV-6? |
| Retrospective outcome analysis |
| Is ciHHV-6 over-represented in some diseases? |
| For example, children with neurological disorders, Hodgkin’s lymphoma, GVHD |
| Prospective analysis: cohorts of individuals with ciHHV-6 |
| Is ciHHV-6 associated with atypical development in children? |
| Is ciHHV-6 associated with peculiar phenotypes (physical or psychological)? |
| Do ciHHV-6 transplant recipients have a greater risk of GVHD or other adverse outcome? |
| Are grafts from ciHHV-6 donors more likely to be rejected or otherwise fail? |
| Can ciHHV-6 be activated in vivo by exposure to common drugs or chemicals? |
| Additional cell culture experiments are required to confirm the finding that ciHHV-6 can be activated in vitro by chemicals such as HDAC inhibitors and hydrocortisone. |
| Are individuals with ciHHV-6 at increased risk when they take drugs known to activate HHV-6 including common anti-seizure drugs valproic acid and carbamazepine? |
| Can individuals with ciHHV-6 acquire HHV-6 horizontally? |
| Are there increased risks for blood transfusion, HSCT or SOT when the donor or recipient has ciHHV-6? |
| What are the risks of transplacental transmission of HHV-6 by ciHHV-6 mothers? |

ciHHV-6, chromosomally integrated human herpesvirus 6; HHV-6, human herpesvirus 6; GVHD, graft-versus-host disease, HSCT, hematopoietic stem cell transplantation; SOT, solid organ transplantation; HDAC, histone deacetylase.
Table 4. Drugs associated with reactivation or enhanced replication of HHV-6

<table>
<thead>
<tr>
<th>Category</th>
<th>In vitro</th>
<th>In vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC inhibitor</td>
<td>Trichostatin A*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sodium n-butyrate</td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Amoxicillin</td>
<td>TMP–SMX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Minocycline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vancomycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dapsone</td>
</tr>
<tr>
<td>Immunosuppressant</td>
<td>Hydrocortisone*</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td></td>
<td>Trichloroethylene</td>
</tr>
<tr>
<td>Anesthetic</td>
<td></td>
<td>Mexiletine</td>
</tr>
<tr>
<td>Anti-arrhythmic</td>
<td></td>
<td>Zonisamide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenobarbitol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lamotrigine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Carbamazepinec</td>
<td>Carbamazepinec</td>
</tr>
<tr>
<td></td>
<td>Valproic Acidc</td>
<td>Zonisamide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenobarbitol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lamotrigine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenytoin</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Ibuprofen</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>TPA (12-O-tetradecanoylphorbol-13-acetate)*</td>
<td>Allopurinol</td>
</tr>
</tbody>
</table>

*See Supplementary Table 1 for additional information and references.

*In vivo associations have been in the context of DIHS, DRESS, TEN, SJS, and AHS.

This drug has HDAC inhibitor properties.

*Also shown to activate chromosomally integrated virus.

**HHV-6, human herpesvirus 6; HDAC, histone deacetylase; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug rash with eosinophilia and systemic symptoms; SJS, Stevens–Johnson syndrome; AHS; anticonvulsant-induced hypersensitivity syndrome; TEN, toxic epidermal necrolysis; NSAIDs, non-steroidal anti-inflammatory drugs.

What is chromosomally integrated human herpesvirus 6?
“Chromosomally integrated human herpesvirus 6” denotes the condition in which the complete HHV-6 genome is integrated into the telomere of a host cell chromosome [42]. Because the viral DNA is integrated into the germline genome, ciHHV-6 can be inherited in a Mendelian manner, with a 50% chance of being passed to a child. In addition, because it is present in germline cells, at least one integrated copy of the HHV-6 genome is presumed to be present in every nucleated cell. Both HHV-6A

well established, and in some cases controversial associations have been reported for Stevens–Johnson syndrome (SJS) [19], renal failure [20,21], hemophagocytic syndrome [22,23], myocarditis [24–26], pneumonitis [27–29], hypogammaglobulinemia [30], and arteriopathies [31,32]. HHV-6A reactivation has been found in subsets of patients with multiple sclerosis [33,34], HIV infection [35–37], encephalitis [38], and syncytial giant-cell hepatitis [39] (reviewed in [40,41]). The vast majority of low-level HHV-6 reactivations in immunocompromised patients are asymptomatic.
and HHV-6B can integrate into the chromosomes; of 34 published examples for which integration sites were mapped, 9 (26%) were HHV-6A and 25 (74%) were HHV-6B (all 10 from Japan reported HHV-6B). In addition to genetic transmission, populations of cells harboring ciHHV-6 may be transmitted via allogenic hematopoietic stem cell transplantation (HSCT) [42–44] and probably via solid organ transplantation (SOT). HHV-6 is the only human herpesvirus known to be integrated into germline chromosomal telomeres. However, Marek’s Disease virus, a herpesvirus of chickens, integrates into chromosomes by a molecular mechanism similar to HHV-6 [45], and EBV can integrate into non-telomeric regions of chromosomes in virally transformed cell lines and Burkitt lymphoma [46].

The prevalence of ciHHV-6 is ~1% in umbilical cord bloods and in healthy blood donors from the USA and UK, 0.2% in hospitalized patients from Japan, and ~2% in patient groups from the USA and UK (Table 5).

### Why is it important to identify individuals with chromosomally integrated human herpesvirus 6?

Identifying individuals with ciHHV-6 is important because every cell in their body harbors the complete HHV-6 genome covalently linked to human chromosomal DNA. Therefore, clinical specimens from such individuals (e.g., whole blood, leukocytes, plasma, and tissue specimens) will contain HHV-6 DNA when tested by PCR assays and will be reported to have high levels of HHV-6 DNA when tested by quantitative PCR. Considering that peripheral blood contains between 4 and 7 million leukocytes (and a

### Table 5. ciHHV-6 prevalence in control and patient populations in Europe, the UK and the United States

<table>
<thead>
<tr>
<th>Study population</th>
<th>Country</th>
<th>ciHHV-6</th>
<th>n</th>
<th>%</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood donors and cord blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cord blood</td>
<td>USA</td>
<td>48</td>
<td>5638</td>
<td>0.85%</td>
<td>[58,77]</td>
</tr>
<tr>
<td>Blood donors</td>
<td>UK</td>
<td>4</td>
<td>500</td>
<td>0.80%</td>
<td>[55]</td>
</tr>
<tr>
<td>Blood donors</td>
<td>USA</td>
<td>1</td>
<td>100</td>
<td>1.00%</td>
<td>[78]</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td>53</td>
<td>6238</td>
<td>0.85%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient groups</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anonymous children’s sera bank</td>
<td>UK</td>
<td>10</td>
<td>653</td>
<td>1.53%</td>
<td>[79]</td>
</tr>
<tr>
<td>Liver transplant patients</td>
<td>US</td>
<td>7</td>
<td>548</td>
<td>1.28%</td>
<td>[80]</td>
</tr>
<tr>
<td>Liver transplant patients</td>
<td>UK</td>
<td>3</td>
<td>60</td>
<td>5.00%</td>
<td>[81]</td>
</tr>
<tr>
<td>Pediatric ALL and myeloid leukemia</td>
<td>Czech Rep</td>
<td>5</td>
<td>339</td>
<td>1.47%</td>
<td>[82]</td>
</tr>
<tr>
<td>HSCT recipients</td>
<td>USA</td>
<td>6</td>
<td>322</td>
<td>1.86%</td>
<td>[12]</td>
</tr>
<tr>
<td>AlloSCT recipients</td>
<td>Italy</td>
<td>1</td>
<td>70</td>
<td>1.43%</td>
<td>[83]</td>
</tr>
<tr>
<td>Children referred for possible encephalitis</td>
<td>UK, Ireland</td>
<td>6</td>
<td>184</td>
<td>3.26%</td>
<td>[84]</td>
</tr>
<tr>
<td>Solid organ transplant recipients</td>
<td>Italy</td>
<td>1</td>
<td>135</td>
<td>0.74%</td>
<td>[83]</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>Italy</td>
<td>2</td>
<td>64</td>
<td>3.13%</td>
<td>[85]</td>
</tr>
<tr>
<td>Hodgkin’s disease</td>
<td>Italy</td>
<td>7</td>
<td>55</td>
<td>12.73%</td>
<td>[85]</td>
</tr>
<tr>
<td>Kidney transplant patients</td>
<td>UK</td>
<td>1</td>
<td>52</td>
<td>1.92%</td>
<td>[86]</td>
</tr>
<tr>
<td>Kidney transplant patients</td>
<td>USA</td>
<td>1</td>
<td>47</td>
<td>2.13%</td>
<td>[87]</td>
</tr>
<tr>
<td>Multiple sclerosis patients</td>
<td>Italy</td>
<td>1</td>
<td>35</td>
<td>2.86%</td>
<td>[85]</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td>51</td>
<td>2564</td>
<td>1.99%</td>
<td></td>
</tr>
</tbody>
</table>

*A chi-square significance test was conducted to determine if these prevalence data are significantly different on a statistical level. The test yielded a p-value of <0.001 when comparing the blood donor and cord blood group with the combined patient population.

ciHHV-6, chromosomally integrated human herpesvirus 6; HSCT, hematopoietic stem cell transplantation; ALL, acute lymphocytic leukemia; AlloSCT, allogeneic stem cell transplant.
corresponding number of viral genomes) per ml, quantitative PCR results for HHV-6 will usually be greater than $1 \times 10^6$ HHV-6 genomes/ml of whole blood. In addition, body fluids that are expected to harbor only small numbers of cells (e.g., serum, plasma, and CSF) will often be positive for HHV-6 DNA by PCR, albeit at lower copy numbers compared with cellular samples, as they contain DNA that has been released by cell lysis due to natural processes or during specimen transport and processing.

The high viral DNA load in patients with ciHHV-6 can lead to misdiagnosis due to the incorrect assumption that the patient is experiencing active HHV-6 infection for which antiviral treatment might be considered [47]. Furthermore, some drugs and chemicals have been shown to induce replication of ciHHV-6 in cell culture (Table 4) [48]. These activities were seen at drug concentrations comparable with levels achieved during therapeutic use. Although there is no evidence that it occurs, clinical use of these or related drugs might activate the virus in patients with ciHHV-6, with unknown clinical consequences. One study of 548 solid organ transplant recipients suggested that those with ciHHV-6 may be at increased risk for bacterial infection and graft rejection [6].

When should chromosomally integrated human herpesvirus 6 screening take place?
No pathology has been conclusively associated with ciHHV-6, thus routine screening is not recommended. However, in certain clinical situations, screening for ciHHV-6 should be considered, such as when there is clinical suspicion for HHV-6 reactivation and the knowledge of the patient’s ciHHV-6 status would influence treatment decisions. For example, ciHHV-6 screening of patients who have high DNA copy numbers may prevent the unnecessary use of antiviral treatment. Testing may also be considered for patients who have had an adverse reaction to a drug previously shown to be associated with HHV-6 reactivation (Table 4).

Can chromosomally integrated human herpesvirus 6 replicate as a virus?
Although triggers for activation of ciHHV-6 in vitro have not been identified, there are suggestions that ciHHV-6 can be induced to a state of lytic (active) viral replication. ciHHV-6 present in cultured lymphocytes of individuals with ciHHV-6 can be induced to lytic replication by histone deacetylase (HDAC) inhibitors, compounds known to reactivate other herpesviruses from latency [48]. Marek’s Disease virus can reactivate to lytic replication from its integrated state in vitro [45,49]. HHV-6 DNA has been detected in the cord blood and saliva of non-ciHHV-6 children born to ciHHV-6 mothers, suggesting the possibility of transplacental transmission of free virus [50].

Which drugs or chemicals might lead to human herpesvirus 6 lytic replication in individuals with chromosomally integrated human herpesvirus 6?
Although evidence is lacking, it is possible that treatment with or exposure to certain pharmaceuticals or chemicals can either directly or indirectly reactivate ciHHV-6. As noted, the HDAC inhibitor Trichostatin A can reactivate HHV-6 in vitro in lymphocytes from individuals with ciHHV-6 [48], and two commonly used pharmaceuticals can enhance HHV-6 replication in vitro and in vivo [51,52] (Table 4). HHV-6 reactivation has been detected by serology and PCR in a high percentage (62%–100%) of patients with DIHS and is also frequently reported in patients with DRESS [21,53]. The mechanism of HHV-6 reactivation during DRESS/DIHS is unknown, but the drugs that activate the virus in these diseases might also activate the virus in individuals with ciHHV-6.

Should certain drugs be avoided in individuals with chromosomally integrated human herpesvirus 6?
It is not known whether ciHHV-6 individuals are put at clinical risk by the use of drugs that have been associated with HHV-6 reactivation in vivo or in vitro. Nonetheless, we urge careful observation when use of such drugs is indicated in individuals known to have ciHHV-6.

What is the best way to identify individuals with chromosomally integrated human herpesvirus 6?
When plasma or serum HHV-6 PCR levels are suspiciously high, the most practical way to confirm that a patient has ciHHV-6 is by quantitative PCR using whole blood or isolated PBMC’s. Individuals
with ciHHV-6 have significantly higher viral DNA loads in PBMC’s and whole blood than do non-ciHHV-6 individuals, even those with primary HHV-6 infection [54]. By quantitative PCR, most healthy adult blood donors have low to undetectable HHV-6 DNA in their whole blood, and in one study of 496 UK blood donors, <2% had HHV-6 DNA levels in the range of 3.2–3.5 log_{10} DNA copies/ml of whole blood [55]. In contrast, individuals with ciHHV-6 have one or more HHV-6 genomic copies per white blood cell, which corresponds to >5.5 log_{10} copies/ml of whole blood [43,54,56], and the high viral DNA loads persist over time [55,57,58]. In contrast, transplant recipients with HHV-6 reactivation and children with primary HHV-6B infection typically have transient virus DNA loads between 1.5 and 5.0 log_{10} copies/ml in whole blood or PBMC’s and less than 5.0 log_{10} copies/ml in serum, respectively [54,59,60]. Rarely, allogeneic HSCT patients with graft-versus-host disease (GVHD) and patients with DIHS/DRESS have been reported to have transient levels >6.0 log_{10} copies/ml in serum and plasma [61]. In contrast to transient viral elevations in these patients, the very high levels of HHV-6 in ciHHV-6 patients are persistent. Thus, if a patient has >5.5 log_{10} copies/ml in whole blood, ciHHV-6 should be considered, and a confirmatory test is recommended (see preceding text).

In individuals with ciHHV-6, the HHV-6 DNA load in blood will vary according to the number of cells included in the specimen, so it is essential to also consider the ratio of viral DNA copies to copies of cellular DNA, especially when the patient has leukopenia or leukocytosis [62] or when testing body fluids such as CSF.

**Can serum or plasma polymerase chain reaction be used to identify and monitor chromosomally integrated human herpesvirus 6?**

Although measuring HHV-6 DNA loads in plasma is widely accepted as a reliable marker of active HHV-6 infection in transplant recipients and other patients, virus monitoring in plasma and serum is unreliable both for identifying and for monitoring subjects with ciHHV-6. Individuals without ciHHV-6 who are experiencing active HHV-6 infections (e.g., during primary infection) sometimes have serum levels as high or higher than routinely seen in individuals with ciHHV-6, although these levels are not persistent. Monitoring ciHHV-6 individuals using plasma is problematic because quantitative PCR results from plasma can vary depending on how quickly the specimen is processed and the limit of detection of the assay. Cell lysis increases as a function of elapsed time between the blood collection and centrifugation, and the extent of lysis can be influenced by factors such as storage temperature and physical forces. Cell lysis during overnight shipping can result in plasma DNA loads in specimens from individuals with ciHHV-6 being significantly higher than a sample from the same blood draw that was separated within a few hours of venipuncture. Plasma samples from individuals with ciHHV-6 centrifuged immediately after a blood draw can test negative for HHV-6 DNA. The clotting process during serum preparation lyases cells and releases cellular DNA, resulting in serum levels of HHV-6 DNA as much as 100-fold higher than in plasma [57].

**Will cerebrospinal fluid from individuals with chromosomally integrated human herpesvirus 6 contain human herpesvirus 6 DNA?**

There are no data for HHV-6 DNA levels in the CSF of healthy ciHHV-6 patients. Individuals with ciHHV-6 who have acute neurological presentations including herpes simplex virus and EBV meningoencephalitis may have high CSF HHV-6 DNA loads (mean 4.0 log_{10} copies/ml) if there is pleocytosis [63]. Because normal CSF may contain up to five nucleated cells per μL, HHV-6 PCR can be positive when using a sensitive assay. However, under circumstances where CSF is relatively acellular, an HHV-6 DNA PCR test could be negative, especially if the assay is insensitive (cutoff >200 copies/ml). Determining the number of viral DNA copies per leukocyte may be helpful.

**Where can physicians send specimens for chromosomally integrated human herpesvirus 6 testing?**

Several commercial and hospital or university laboratories offer whole blood testing for HHV-6 by quantitative PCR in the USA, Europe, and
Can whole blood quantitative polymerase chain reaction results be used to monitor chromosomally integrated human herpesvirus 6 patients?

In HSCT or SOT recipients, the presence of ciHHV-6 complicates the interpretation of quantitative PCR data because the amount of additional HHV-6 DNA resulting from active replication is most likely a small fraction of the amount that would already be present at baseline due to the ciHHV-6.

There is no demonstrated value for routinely monitoring HHV-6 DNA levels in individuals with ciHHV-6, the precision of quantitation at such high copy numbers has not been documented, and there is no proven framework for interpreting such data.

Is it necessary to test hair follicles or nails or to perform fluorescence in situ hybridization to confirm chromosomally integrated human herpesvirus 6?

No. Whole blood quantitative PCR testing provides a high level of certainty as to whether an individual has ciHHV-6. Confirmation can be made by testing the patient’s parents or siblings, or sequential testing of the patient to demonstrate persistence of high HHV-6 DNA. For ciHHV-6, which is passed through the germline, at least one biological parent would carry ciHHV-6.

DNA PCR testing of hair follicles or nails can confirm ciHHV-6 status, because only ciHHV-6 individuals have detectable HHV-6 DNA in these tissues [57,65]. These assays might be useful when obtaining blood samples is complicated, particularly in developing countries. Fluorescence in situ hybridization analysis can also establish probable integration, but such assays are complex and are not necessary for diagnostic purposes given the availability of quantitative PCR testing.

Identification of ciHHV-6 can be considered as a form of genetic testing that can unintentionally illuminate issues related to biological parentage (e.g., a child is positive for ciHHV-6 and both parents are negative). Consultation with a genetic counselor might be warranted.

Do individuals with chromosomally integrated human herpesvirus 6 produce antibodies against human herpesvirus 6 antigens?

Antibodies against HHV-6 proteins might be generated against viral proteins expressed from an otherwise quiescent chromosomally integrated virus genome during latency, during lytic reactivation of the chromosomally integrated genome, and during infection with a community acquired virus. Little is known about whether and how the chromosomally integrated virus might affect the immune response during active infections, for example, whether immune tolerance develops for some viral proteins. In one study, it appeared that antibody levels among those with ciHHV-6 might be reduced; only 14% of ciHHV-6 individuals had antibodies to HHV-6 glycoprotein B, compared with 60% without ciHHV-6 [66].

How can you tell if an individual with chromosomally integrated human herpesvirus 6 has active human herpesvirus 6 infection?

A single quantitative PCR test on serum or plasma cannot prove whether a patient with ciHHV-6 has active HHV-6 infection, whether due to activation of ciHHV-6 or horizontally acquired. Neither serum nor plasma PCR is definitive for this purpose. Quantitative reverse transcriptase PCR that monitors the expression of HHV-6 genes associated with productive infection (e.g., structural genes) might be useful for the identification of active infections, but such assays are not generally available and their clinical utility for monitoring HHV-6 activity in individuals with ciHHV-6 has not been defined. Alternatively, active HHV-6 infections can be detected using a quantitative antigenemia assay that measures the frequency of peripheral blood leukocytes that express lytic antigens [67,68], but such an assay has not been evaluated in the context of ciHHV-6. Physicians must, therefore, use clinical judgment to determine if the patient is experiencing a disease typically associated with HHV-6.

What treatments are effective for human herpesvirus 6 infections?

No drugs have been specifically approved for HHV-6 infections by government agencies, and no
large trials have confirmed that antivirals are effective against HHV-6 in vivo. Several small studies have demonstrated that prophylactic antiviral treatment inhibits reactivation and may reduce the number of neurological events in HSCT patients [69–71]. Although most strains of HHV-6A and HHV-6B are susceptible to both ganciclovir and foscarnet, some HHV-6B strains are resistant to ganciclovir [72]. Neither acyclovir nor penciclovir are effective against either HHV-6A or HHV-6B. Ganciclovir, foscarnet, and cidofovir are approved for treatment of the closely related betaherpesvirus CMV and have been used to treat HHV-6 diseases such as encephalitis in the post-transplant setting [68,72,73]. Valganciclovir decreased the incidence of HHV-6 viremia in SOT recipients, and ganciclovir prophylaxis delayed and shortened HHV-6 viremia in renal transplant recipients. Ganciclovir treatment of CMV disease in liver transplant patients reduced concurrent HHV-6 antigenemia, although the response was slower than for CMV [74]. HHV-6 infections in allogeneic HSCT patients have been successfully treated with foscarnet [68,69,75]. In immunocompromised hosts, reduction in pharmacologic immunosuppression to improve T cell function is an important and often essential component of therapy for HHV-6.

**Should patients with chromosomally integrated human herpesvirus 6 be treated for human herpesvirus 6?**

There is no basis to recommend treatment of asymptomatic individuals with ciHHV-6 for their resident viral DNA [76]. It is not known whether individuals with ciHHV-6 are more prone to develop active HHV-6 infections or whether such hypothetical infections cause any disease. Nevertheless, antiviral therapy might be warranted if patients present with clinical manifestations typically associated with reactivated HHV-6 infection. In all instances, alternative and concurrent causes of the clinical manifestations should be sought, such as CMV and other herpesviruses, even when the clinical symptoms are consistent with those associated with HHV-6. Although some ciHHV-6 patients with encephalitis and encephalomyelitis [21,52] have appeared to respond to antiviral treatment, in other cases, the therapy was ineffective [46,76].

**How should chromosomally integrated human herpesvirus 6 families be advised on pregnancy?**

Little is known about ciHHV-6 and pregnancy [50]. No published studies have suggested a reason to avoid pregnancy or that ciHHV-6 individuals bear an increased risk of developing specific diseases.

**Should individuals with chromosomally integrated human herpesvirus 6 refrain from donating blood, stem cells, ova, sperm, or organs?**

Case reports of HSCT from ciHHV-6 positive individuals to negative recipients suggest that ciHHV-6 individuals can successfully donate [43,44]. However, only a handful of such cases have been studied. The possibility that donated blood, blood products, cells, or tissues from individuals with ciHHV-6 might cause clinical problems requires further study.

**FUNDING:**

This project was supported by the HHV-6 Foundation. Several of the co-authors have received research grants from the HHV-6 Foundation.

**ACKNOWLEDGEMENTS**

We would like to acknowledge Louise Chatlynne, PhD for her assistance in the preparation of this manuscript as well as the HHV-6 Foundation for administrative support.

**CONFLICT OF INTEREST**

No potential conflicts of interest are reported.

**Key points**

- Approximately 1% of the population harbors germline ciHHV-6.
- Because it is transmitted via the germ-line, the HHV-6 genome is present in every nucleated cell in the body.
- HHV-6 levels in whole blood $>5.5 \log_{10}$ copies/ml are suggestive of ciHHV-6.
- ciHHV-6 transplant patients may be more likely to experience GVHD and bacterial infections.
- Integrated HHV-6 can be activated in vitro.
- ciHHV-6 can lead to the misdiagnosis of reactivated HHV-6 infection.
REFERENCES


64. HHV-6-Foundation. CIHHV-6 Testing Information. 2011 [cited 2011 August 22, 2011]; Available from: http://www.hhv-6foundation.org/clinicians/cihhv-6-testing.


